Early lung fluid study in sepsis-related breathing failure
Part of Infections, Lungs & breathing clinical trials.
This study looks at the early changes in the lungs of people with sepsis who develop a severe breathing problem called ARDS. Researchers will collect small samples of lung fluid to better understand the condition and potentially improve future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have sepsis or septic shock (a severe infection that affects your organs).
- You must need a breathing machine (invasive mechanical ventilation) within 72 hours of being diagnosed with sepsis.
- You cannot be pregnant, have had a lung transplant, or have any reason that prevents safe lung sampling.
- You (or a legal representative) must provide written consent, and you must be able to complete two lung sampling procedures within 96 hours.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at patients with sepsis (a severe infection that affects organs) and acute respiratory distress syndrome (ARDS, a serious lung condition) to learn more about these illnesses and improve care.
This study examines lung fluid samples and imaging scans from patients on breathing machines to better understand acute respiratory distress syndrome (ARDS), a serious lung condition. Researchers hope this will help doctors diagnose and treat ARDS more effectively in the future.
This study collects blood samples from people in the ICU with sudden heart or lung problems caused by inflammation. The goal is to learn more about these conditions and improve future treatments.
This study looks at two substances in saliva and lung fluid—called IL-6 and TNF-α—in children with severe lung failure (ARDS) who are on a breathing machine. Measuring these markers may help doctors better understand the condition and guide treatment.
This trial tests a new medicine called YD0743 for people who have both sepsis (a serious infection) and ARDS (a severe lung injury from the infection). The goal is to see if the medicine helps improve breathing and survival.
This study looks at certain markers in the blood to help predict and understand lung injury in people who have sepsis from an infection outside the lungs. By joining, you help doctors learn how to better protect the lungs of future patients with sepsis.
Hear when a new Acute Hypoxemic Respiratory Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.